In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
CRA's Competition & Antitrust Practice commemorates Canada Day
Our Toronto team advises clients on complex antitrust, merger, and regulatory matters in Canada, Europe, and the United States. We would like to take this...